Mr. Richard Glickman reports
AURINIA ENHANCES RESEARCH, DEVELOPMENT, AND SCIENTIFIC EXPERTISE WITH THE APPOINTMENT OF MICHAEL HAYDEN TO ITS BOARD OF DIRECTORS
Aurinia Pharmaceuticals Inc. has appointed Dr. Michael
Hayden, CM, OBC, MB, ChB, PhD, FRCP, FRSC, to its board of directors. Dr.
Hayden was most recently the president of global research and development and chief
scientific officer at Teva.
"Michael's scientific acumen and clinical development track record is
unparalleled in this industry," said Richard M. Glickman, chief
executive officer and chairman of the board of Aurinia. "His skill set
rounds out our board with world-class research and development
experience, which will prove extremely valuable as we initiate our new
indications and assess strategic growth options for Aurinia."
Dr. Hayden was recently named one of the 50 Canadians born in the 20th
century who have changed the world. He is the co-founder of three
biotechnology companies: NeuroVir Therapeutics Inc., Xenon
Pharmaceuticals Inc. and Aspreva Pharmaceuticals Corp. Dr. Hayden sits
on different boards, including Xenon Pharmaceuticals and Lycera. Author
of over 860 peer-reviewed publications and invited submissions, Dr.
Hayden has focused his research primarily on genetic diseases, including
genetics of diabetes, lipoprotein disorders, Huntington disease,
and predictive and personalized medicine. Dr. Hayden was inducted into the
Canadian Medical Hall of Fame in 2017. He was named one of PharmaVoice's
100 of the most inspiring people (2015); awarded an honorary doctor of
science by the University of Gottingen (2014); the luminary award by the
Personalized Medicine World Conference (2014); and the Diamond Jubilee
Medal (2012), on behalf of the Queen, in recognition of his
significant contributions and achievements. Dr. Hayden has also been
awarded the Order of Canada (2011) and the Order of British Columbia
(2010). He was named Canada's health researcher of the year by CIHR (NIH
of Canada) in 2008, and he received the Prix Galien in 2007, which
recognizes the outstanding contribution of a researcher to Canadian
pharmaceutical research.
"I hope to build upon the success we created as a team at Aspreva in
improving the treatment paradigm for lupus nephritis," said Dr. Hayden.
"Aurinia's commitment to addressing the significant unmet medical need
in lupus nephritis is highly encouraging for patients, and I look
forward to once again working alongside this exceptional management team
as we pursue a successful future for the company."
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.